company background image

RPG Life Sciences BSE:532983 Stock Report

Last Price


Market Cap







24 May, 2022


Company Financials
532983 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance5/6
Financial Health6/6

532983 Stock Overview

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.

RPG Life Sciences Competitors













Price History & Performance

Summary of all time highs, changes and price drops for RPG Life Sciences
Historical stock prices
Current Share Price₹494.60
52 Week High₹751.80
52 Week Low₹425.00
1 Month Change-14.83%
3 Month Change-0.76%
1 Year Change10.08%
3 Year Change93.81%
5 Year Change32.32%
Change since IPO1,027.94%

Recent News & Updates

Shareholder Returns

532983IN PharmaceuticalsIN Market

Return vs Industry: 532983 exceeded the Indian Pharmaceuticals industry which returned -10.3% over the past year.

Return vs Market: 532983 exceeded the Indian Market which returned 8.6% over the past year.

Price Volatility

Is 532983's price volatile compared to industry and market?
532983 volatility
532983 Average Weekly Movement7.9%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement7.0%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.6%

Stable Share Price: 532983 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 532983's weekly volatility (8%) has been stable over the past year.

About the Company

19681,107Yugal Kishor Sikri

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, oncology, urology, respiratory, vitamins and minerals, gastro intestinal, pain management, cardio-vascular, etc. primarily under the Lomotil, Lomofen+, Naprosyn, Azoran, Aldactone, and Serenace brand names. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008.

RPG Life Sciences Fundamentals Summary

How do RPG Life Sciences's earnings and revenue compare to its market cap?
532983 fundamental statistics
Market Cap₹8.18b
Earnings (TTM)₹514.80m
Revenue (TTM)₹4.40b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
532983 income statement (TTM)
Cost of Revenue₹1.42b
Gross Profit₹2.98b
Other Expenses₹2.47b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)31.13
Gross Margin67.78%
Net Profit Margin11.70%
Debt/Equity Ratio0.1%

How did 532983 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is RPG Life Sciences undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 532983 (₹494.6) is trading below our estimate of fair value (₹645.1)

Significantly Below Fair Value: 532983 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 532983 is good value based on its Price-To-Earnings Ratio (15.9x) compared to the Indian Pharmaceuticals industry average (20.7x).

PE vs Market: 532983 is good value based on its Price-To-Earnings Ratio (15.9x) compared to the Indian market (20.4x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 532983's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 532983 is overvalued based on its Price-To-Book Ratio (3.2x) compared to the IN Pharmaceuticals industry average (2.7x).

Future Growth

How is RPG Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has RPG Life Sciences performed over the past 5 years?

Past Performance Score


Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 532983 has high quality earnings.

Growing Profit Margin: 532983's current net profit margins (11.7%) are higher than last year (10.3%).

Past Earnings Growth Analysis

Earnings Trend: 532983's earnings have grown significantly by 36.3% per year over the past 5 years.

Accelerating Growth: 532983's earnings growth over the past year (28.7%) is below its 5-year average (36.3% per year).

Earnings vs Industry: 532983 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry 12.5%.

Return on Equity

High ROE: 532983's Return on Equity (20.1%) is considered high.

Financial Health

How is RPG Life Sciences's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 532983's short term assets (₹2.1B) exceed its short term liabilities (₹801.1M).

Long Term Liabilities: 532983's short term assets (₹2.1B) exceed its long term liabilities (₹87.3M).

Debt to Equity History and Analysis

Debt Level: 532983 has more cash than its total debt.

Reducing Debt: 532983's debt to equity ratio has reduced from 30.2% to 0.1% over the past 5 years.

Debt Coverage: 532983's debt is well covered by operating cash flow (22327.6%).

Interest Coverage: 532983's interest payments on its debt are well covered by EBIT (136x coverage).

Balance Sheet


What is RPG Life Sciences's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 532983's dividend (1.94%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).

High Dividend: 532983's dividend (1.94%) is in the top 25% of dividend payers in the Indian market (1.62%)

Stability and Growth of Payments

Stable Dividend: 532983's dividend payments have been volatile in the past 10 years.

Growing Dividend: 532983's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (30.8%), 532983's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (38.9%), 532983's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Yugal Kishor Sikri (64 yo)





Mr. Yugal Kishor Choturam Sikri has been Managing Director and Director at RPG Life Sciences Limited since October 1, 2018 He served as an Independent & Non-Executive Director at RPG Life Sciences Limited...

CEO Compensation Analysis

Compensation vs Market: Yugal Kishor's total compensation ($USD505.14K) is above average for companies of similar size in the Indian market ($USD38.56K).

Compensation vs Earnings: Yugal Kishor's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: 532983's management team is considered experienced (4.3 years average tenure).

Board Members

Experienced Board: 532983's board of directors are considered experienced (7.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

RPG Life Sciences Limited's employee growth, exchange listings and data sources

Key Information

  • Name: RPG Life Sciences Limited
  • Ticker: 532983
  • Exchange: BSE
  • Founded: 1968
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹8.180b
  • Shares outstanding: 16.54m
  • Website:

Number of Employees


  • RPG Life Sciences Limited
  • 463, Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.